

## **TSH Biopharm acquires the commercialization right of all CellMax Life liquid-biopsy diagnosis products**

2019/02/13

TSH Biopharm (8432) announced today to strategically invested in the US company CellMax Cayman and signed a distribution contract with its subsidiary CellMax Life (hereafter referred to as CellMax Life) to acquire the exclusive commercialization right of all CellMax Life liquid-biopsy diagnosis products and subsequent new products in territory of Taiwan, and non-exclusive commercialization right of Southeast Asia and Korea. TSH Biopharm is also granted the right of first refusal of the commercialization right in China according to the collaboration agreement.

CellMax Life, a liquid biopsy company with a proprietary platform for detecting pre-cancer and cancer cells in blood, will be the first diagnostics partner for the TSH Biopharm. CellMax Life offers the most prescribed liquid biopsy test in Taiwan. By combining the proprietary CTC CMx platform with the CellMax SMSEQ ctDNA based liquid biopsy platform, CellMax uniquely offers oncology diagnostic tests with CTC and ctDNA liquid biopsy technologies across the continuum of care.

“With personalized medicine solutions, cancer can be managed like a chronic disease, enhancing quality of life for patients, and positively impacting survival rates. Expansion into multi-analyte oncology diagnostics is one of the top strategic priorities for our company, driven by demand from oncologists, patients and consumers,” said Sze Yuan Yang, new GM of TSH Biopharm. “We elected to partner with CellMax Life because they offer the most comprehensive menu of tests for cancer prevention, early-detection, treatment and monitoring. We were particularly impressed with the sensitivity of the CellMax Life circulating tumor cell platform CMx for the detection of colorectal cancer presented at ASCO's gastrointestinal symposium in 2019. Further, CellMax' s CAP accredited Lab in Taiwan allows for a fast turnaround and local support.”

### **About TSH Biopharm**

TSH Biopharm Co., Ltd. was one of the business units of TTY Biopharm and formed in 2003, later spin-off from TTY Biopharm in late 2010. Since its spin-off, TSH Biopharm has been dedicated to the drug development of chronic disease as well as the marketing of specialty drugs in Taiwan and ASEA.

### **About CellMax Life**

CellMax Life is a liquid biopsy company with a proprietary platform for the detection of pre-cancer and colorectal cancer in a single blood sample. The company has a CLIA- & CAP-accredited lab in Sunnyvale, California and a CAP-accredited lab in Taipei, Taiwan. Visit <https://cellmaxlife.com> and <https://tw.cellmaxlife.com/>.